BRUSSELS, Nov 4 (Reuters) - EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of contract drug manufacturer Catalent , according to a filing on the European Commission website on Monday.
The controlling shareholder of Novo Nordisk put in a request for EU approval for the deal on Oct. 31, the filing showed.
The EU antitrust can either clear the deal with or without remedies or it can open a full-scale four-month long investigation if it has serious concerns.
(Reporting by Foo Yun Chee)
((foo.yunchee@thomsonreuters.com; +32 2 585 2866; Reuters Messaging: foo.yunchee.thomsonreuters.com@reuters.net))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。